A.D.A.M. Innovations Expands GeneAI Forecast with New Chronic Disease Models

A.D.A.M. Innovations Co., a genomic intelligence and precision health company based in Tokyo, has expanded its GeneAI Forecast service to include new chronic disease risk assessment models for asthma, atopic dermatitis, and chronic obstructive pulmonary disease (COPD). This update brings the total number of disease risk assessments offered by the platform to 18, covering a range of conditions including lifestyle-related risks, chronic diseases, progressive diseases, and cancer risks.

The company's latest enhancements to GeneAI Forecast also integrate average resting heart rate data from health apps and wearable devices, alongside existing biomarkers such as BMI, blood pressure, and glucose levels. The new feature allows users to gain a more comprehensive view of their health by incorporating physiological information into the platform.

Michel Mommejat, President and Chief Innovation Officer of A.D.A.M. Innovations, stated, "GeneAI Forecast is evolving from a static view of genetic predisposition towards a more dynamic understanding of health risk. By expanding our risk assessment models and integrating physiological information from connected health technologies, we are bringing genomic intelligence together with real-world health data. Our goal is to give individuals a more personalized and dynamic view of their health and support a more proactive approach to prevention."

GeneAI Forecast now includes the following 18 predictive models: - Lifestyle-related risks: Hypertension, Type 2 Diabetes, Myocardial Infarction, Stroke, Chronic Kidney Disease - Chronic diseases: Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease (COPD), Irritable Bowel Syndrome (IBS), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - Progressive diseases: Osteoarthritis, Osteoporosis - Cancer risks: Lung Cancer, Stomach Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer (female-specific), Prostate Cancer (male-specific)

Users can access the new models and resting heart rate biomarker through the Genesis CONNECT and WGS CONNECT subscription plans. The platform continues to integrate with leading health applications and wearable devices, such as Apple Health and Google Fit, to provide a more holistic view of individual health profiles.

GeneAI Forecast is designed to support health awareness and provide users with informational insights into potential health risks. It is not intended to provide medical diagnoses or treatment recommendations. The company emphasizes that results represent risk assessments within predefined risk categories established on the basis of medically and scientifically grounded criteria, based on available genomic, health, and other data.